Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Single-agent nivolumab showed durable responses, manageable safety, and promising survival in patients with advanced hepatocellular carcinoma in the phase 1–2 CheckMate 040 study. We aimed to investigate nivolumab monotherapy compared with sorafenib monotherapy in the first-line setting for patients...

Full description

Saved in:

Bibliographic Details
Published in:	The lancet oncology Vol. 23; no. 1; pp. 77 - 90
Main Authors:	Yau, Thomas, Park, Joong-Won, Finn, Richard S, Cheng, Ann-Lii, Mathurin, Philippe, Edeline, Julien, Kudo, Masatoshi, Harding, James J, Merle, Philippe, Rosmorduc, Olivier, Wyrwicz, Lucjan, Schott, Eckart, Choo, Su Pin, Kelley, Robin Kate, Sieghart, Wolfgang, Assenat, Eric, Zaucha, Renata, Furuse, Junji, Abou-Alfa, Ghassan K, El-Khoueiry, Anthony B, Melero, Ignacio, Begic, Damir, Chen, Gong, Neely, Jaclyn, Wisniewski, Tami, Tschaika, Marina, Sangro, Bruno
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.01.2022 Elsevier Limited Elsevier
Subjects:	Adverse events Aged Antiangiogenic agents Apoptosis Aspartate aminotransferase Cancer Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - psychology Clinical medicine Clinical trials Drug dosages Female Hematology, Oncology, and Palliative Medicine Hepatitis Hepatitis C Hepatocellular carcinoma Humans Immunotherapy Inhibitor drugs Life Sciences Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - mortality Liver Neoplasms - psychology Male Middle Aged Monoclonal antibodies Nivolumab - adverse effects Nivolumab - therapeutic use Patients Protein-tyrosine kinase Safety Sorafenib - adverse effects Sorafenib - therapeutic use Survival Targeted cancer therapy Toxicity Transplants & implants Asia
ISSN:	1470-2045, 1474-5488, 1474-5488
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!